Therapeutic plasma exchange for the treatment of systemic sclerosis: A comprehensive review and analysis

Edward S Harris, Herbert J Meiselman, Patrick M Moriarty, Allan Metzger, Miroslav Malkovsky, Edward S Harris, Herbert J Meiselman, Patrick M Moriarty, Allan Metzger, Miroslav Malkovsky

Abstract

Background: Therapeutic plasma exchange has been tried as a treatment approach for systemic sclerosis since 1978 based on the rationale that some circulating factor is involved in disease pathogenesis, for example, autoantibodies or immune complexes, and that removing the potential pathogenic factors could lead to symptom improvement. Based on our impression that clinicians and researchers are largely unaware that a large volume of research has been published about the use of therapeutic plasma exchange as a treatment for systemic sclerosis, we conducted a comprehensive review and analysis of all published research on this topic.

Results: We identified 46 relevant articles that met our search criteria, involving a total of 572 patients. Of these, 19 were case studies; the rest ranged from small observational studies to prospective randomized clinical trials. In all but two studies, most patients receiving therapeutic plasma exchange showed improvements in both clinical symptoms and laboratory markers, including significant improvement in Raynaud's symptoms and healing of digital ulceration after three to four weekly treatments. The beneficial effects from even a short course of therapeutic plasma exchange treatments were long-lasting, typically 6 months or longer. Therapeutic plasma exchange was very well tolerated. Adverse events were rare and, in almost all cases, mild and transitory.

Conclusion: These results suggest that long-term therapeutic plasma exchange may offer a low-risk way to control and in some cases reverse systemic sclerosis symptoms. The mechanism for the clinical improvements seen from therapeutic plasma exchange in systemic sclerosis patients is unclear. Therefore, additional studies of therapeutic plasma exchange effects in systemic sclerosis appear to be highly desirable.

Keywords: Therapeutic plasma exchange; hyperviscosity; mixed connective tissue disorder; plasmapheresis; systemic sclerosis; therapeutic apheresis.

Conflict of interest statement

Declaration of conflicting interests: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

© The Author(s) 2018.

Figures

Figure 1.
Figure 1.
Potential Impact of RBC Aggregation on Endothelial Integrity.

References

    1. Steen VD, Medsger TA. Changes in causes of death in systemic sclerosis, 1972–2002. Ann Rheum Dis 2007; 66(7): 940–944.
    1. Elhai M, Meune C, Avouac J, et al. . Trends in mortality in patients with systemic sclerosis over 40 years: a systematic review and meta-analysis of cohort studies. Rheumatology 2012; 51(6): 1017–1026.
    1. Patten E, Berkman EM. Therapeutic plasmapheresis and plasma exchange. Crit Rev Clin Lab Sci 1986; 23(2): 147–175.
    1. Winters JL. Plasma exchange: concepts, mechanisms, and an overview of the American Society for Apheresis guidelines. Hematol Am Soc Hematol Educ Progr 2012; 2012: 7–12.
    1. MINISTERIAL DECREE May 28, 1999, no. 329. Regulation laying down rules for the detection of chronic and disabling diseases within the meaning of Article 5 (1) (a) of Legislative Decree no. 124. (GU General Series No.226 of 25-9-1999 - Ordinary Supplement No 174).
    1. National Coverage Determination (NCD) for Apheresis (Therapeutic Pheresis) (110.14).
    1. Schwartz J, Padmanabhan A, Aqui N, et al. . Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Writing Committee of the American Society for Apheresis: the seventh special issue. J Clin Apher 2016; 31(3): 149–162.
    1. Harris E, Moriarty P, Meiselman H. Therapeutic plasma exchange for the treatment of systemic scleroderma: a comprehensive review and analysis. J Clin Apher 2016; 31(2): A90.
    1. Tufanaru C, Munn Z, Aromataris E, et al. . Systematic reviews of effectiveness. In: Aromataris E, Munn Z. (eds) Joanna Briggs Institute reviewer’s manual. The Joanna Briggs Institute, 2017,
    1. Dreyer NA, Bryant A, Velentgas P. The GRACE checklist: a validated assessment tool for high quality observational studies of comparative effectiveness. J Manag Care Spec Pharm 2016; 22(10): 1107–1113.
    1. National Institutes of Health National Heart Lung Blood Institute. “Quality assessment tool for before-after (pre-post) studies with no control group.” Systematic evidence reviews and clinical practice guidelines. Washington DC: National Institutes of Health, 2014.
    1. Moola S, Munn Z, Tufanaru C, et al. . Systematic reviews of etiology and risk. In: Aromataris E, Munn Z. (eds) Joanna Briggs Institute reviewer’s manual. The Joanna Briggs Institute, 2017,
    1. Ding C, Zhang X. A prospective study of plasma exchange in the treatment of diffuse scleroderma. Zhonghua Nei Ke Za Zhi 1995; 34(9): 616–619.
    1. Weiner S, Kono D, Osterman H, et al. . Preliminary report on a controlled trial of apheresis in the treatment of scleroderma. Arthritis Rheum 1987; 30: S24.
    1. Akesson A, Wollheim FA, Thysell H, et al. . Visceral improvement following combined plasmapheresis and immunosuppressive drug therapy in progressive systemic sclerosis. Scand J Rheumatol 1988; 17(5): 313–323.
    1. Cozzi F, Marson P, Rosada M, et al. . Long-term therapy with plasma exchange in systemic sclerosis: effects on laboratory markers reflecting disease activity. Transfus Apher Sci 2001; 25(1): 25–31.
    1. Von Rhede van der Kloot EJH, Jacobs MJHM, Weber H, et al. . Plasma filtration in patients with Raynaud’s phenomenon. Clin Hemorheol Microcirc 1985; 5(1): 79–84.
    1. Weber H, Schmid-Schonbein H, Lemmens HA. Plasmapheresis as a treatment of Raynaud’s attacks: microrheological differential diagnosis and evaluation of efficacy. Clin Hemorheol Microcirc 1985; 5: 85–97.
    1. Cozzi F, Marson P, Cardarelli S, et al. . Prognosis of scleroderma renal crisis: a long-term observational study. Nephrol Dial Transplant 2012; 27(12): 4398–4403.
    1. Marson P, Cozzi F, Silvestro G De, et al. . Il trattamento a lungo termine con plasma-exchange nella sclerosi sistemica. La Trasfus Del Sangue 2001; 46(1): 10–16.
    1. Guillevin L, Amoura Z, Merviel P, et al. . Treatment of progressive systemic sclerosis by plasma exchange: long-term results in 40 patients. Int J Artif Organs 1990; 13(2): 125–129.
    1. Jacobs MJ, Jörning PJ, Van Rhede van der Kloot EJ, et al. . Plasmapheresis in Raynaud’s phenomenon in systemic sclerosis: a microcirculatory study. Int J Microcirc Clin Exp 1991; 10(1): 1–11.
    1. Schmidt C, Schooneman F, Siebert P, et al. . Treatment of systemic scleroderma using plasma exchange. A study of 19 cases. Ann Med Interne 1988; 139(Suppl. 1): 20–22.
    1. Zahavi J, Hamilton WAP, O’Reilly MJG, et al. . Plasma exchange and platelet function in Raynaud’s phenomenon. Thromb Res 1980; 19(1–2): 85–93.
    1. Dodds AJ, O’Reilly MJ, Yates CJ, et al. . Haemorrheological response to plasma exchange in Raynaud’s syndrome. Br Med J 1979; 2(6199): 1186–1187.
    1. O’Reilly MJ, Talpos G, Roberts VC, et al. . Controlled trial of plasma exchange in treatment of Raynaud’s syndrome. Br Med J 1979; 1(6171): 1113–1115.
    1. Ferri C, Bernini L, Gremignai G, et al. . Plasma exchange in the treatment of progressive systemic sclerosis. Plasma Ther Transfus Technol 1987; 8(2): 169–176.
    1. McCune MA, Winkelmann RK, Osmundson PJ, et al. . Plasma exchange: a controlled study of the effect in patients with Raynaud’s phenomenon and scleroderma. J Clin Apher 1983; 1(4): 206–214.
    1. Hamilton W, White J, Cotton L. Circulatory improvement in Raynaud’s phenomenon following plasma exchange. In: Sieberth HG. (ed.) Plasma exchange. Stuttgart; New York: Schattauer, 1980, pp. 301–307.
    1. O’Reilly MJ, Dodds AJ, Roberts VC, et al. . Plasma exchange and Raynaud’s phenomenon: its assessment by Doppler ultrasound velocimetry. Br J Surg 1979; 66(10): 712–715.
    1. Talpos G, Horrocks M, White JM, et al. . Plasmapheresis in Raynaud’s disease. Lancet 1978; 1(8061): 416–417.
    1. Vlasenko AN, Vorob’ev AA, Matveev SI. Clinical effectiveness of plasmapheresis and lymphocytoplasmapheresis in patients with systemic scleroderma. Klin Med 1992; 70(2): 57–61.
    1. Cotton LT. Plasmapheresis in Raynaud’s disease. Lancet 1978; 2(8080): 108.
    1. Zhang H, Liang J, Tang X, et al. . Sustained benefit from combined plasmapheresis and allogeneic mesenchymal stem cells transplantation therapy in systemic sclerosis. Arthritis Res Ther 2017; 19(1): 165.
    1. Dau PC, Callahan JP. Immune modulation during treatment of systemic sclerosis with plasmapheresis and immunosuppressive drugs. Clin Immunol Immunopathol 1994; 70(2): 159–165.
    1. Mascaro G, Cadario G, Bordin G, et al. . Plasma exchange in the treatment of nonadvanced stages of progressive systemic sclerosis. J Clin Apher 1987; 3(4): 219–225.
    1. Pourrat JP, Begasse F, Thierry FX, et al. . Plasma exchange therapy in progressive systemic sclerosis. Plasma Ther Transfus Technol 1987; 8(2): 113–118.
    1. Dau PC, Kahaleh MB, Sagebiel RW. Plasmapheresis and immunosuppressive drug therapy in scleroderma. Arthritis Rheum 1981; 24(9): 1128–1136.
    1. Guillevin L, Leon A, Levy Y, et al. . Treatment of progressive systemic sclerosis with plasma exchange. Seven cases. Int J Artif Organs 1983; 6(6): 315–318.
    1. Harris E, Meiselman H, Moriarty P, et al. . Successful long-term (22 year) treatment of limited scleroderma using therapeutic plasma exchange: is blood rheology the key? Clin Hemorheol Microcirc 2017; 65: 131–136.
    1. Dodds EM, Lowder CY, Foster RE. Plasmapheresis treatment of central retinal vein occlusion in a young adult. Am J Ophthalmol 1995; 119(4): 519–521.
    1. Ferri C, Bernini L, Gremignai G, et al. . Lung involvement in systemic sclerosis sine scleroderma treated by plasma exchange. Int J Artif Organs 1992; 15(7): 426–431.
    1. Hertzman A, Cooke CL, Rodriquez GE, et al. . Treatment of childhood mixed connective tissue disease with plasmapheresis. Clin Immunol Newsl 1981; 2(18): 142–144.
    1. Owlia MB. Plasma exchange in progressive systemic sclerosis. Am J Exp Clin Res 2015; 2(4): 133–135.
    1. Llewelyn MB, Lockwood CM. (10) Plasmapheresis in the CREST syndrome. Br J Dermatol 1989; 121(s34): 78–79.
    1. Capodicasa G, De Santo NG, Galione A, et al. . Clinical effectiveness of apheresis in the treatment of progressive systemic sclerosis. Int J Artif Organs 1983; 6(Suppl. 1): 81–86.
    1. Kamanabroo D, Lonauer G, Knob J. Plasmapheresis in the treatment of mixed connective tissue disease. In: Plasmapheresis. Stuttgart; New York: Schattauer, 1980, p. 283.
    1. Nagamura N, Kin S. Scleroderma renal crisis during intravenous cyclophosphamide pulse therapy for complicated interstitial lung disease was successfully treated with angiotensin converting enzyme inhibitor and plasma exchange. Nagoya J Med Sci 2016; 78(3): 329–334.
    1. Szekanecz Z, Aleksza M, Antal-Szalmás P, et al. . Combined plasmapheresis and high-dose intravenous immunoglobulin treatment in systemic sclerosis for 12 months: follow-up of immunopathological and clinical effects. Clin Rheumatol 2009; 28(3): 347–350.
    1. Kfoury Baz EM, Mahfouz RA, Masri AF, et al. . Thrombotic thrombocytopenic purpura in a case of scleroderma renal crisis treated with twice-daily therapeutic plasma exchange. Ren Fail 2001; 23(5): 737–742.
    1. Ferri C, Emdin M, Storino F, et al. . Isolated pulmonary hypertension in diffuse cutaneous systemic sclerosis successfully treated with long-term plasma exchange: case report. Scand J Rheumatol 2000; 29(3): 198–200.
    1. Seguchi M, Soejima Y, Tateishi A, et al. . Mixed connective tissue disease with multiple organ damage. Successful treatment with plasmapheresis. Intern Med 2000; 39(12): 1119–1122.
    1. Tamura K, Akiyama J, Oono K, et al. . A successful therapy with plasma exchange for interstitial pneumonia of progressive systemic sclerosis. Intern Med 1992; 31(5): 649–654.
    1. Crapper RM, Dowling JP, Mackay IR, et al. . Acute scleroderma in stable mixed connective tissue disease: treatment by plasmapheresis. Aust N Z J Med 1987; 17(3): 327–329.
    1. Gouet D, Alcalay D, Thomas P, et al. . Traitement de la sclérodermie généralisée par échanges plasmatiques. La Rev Médecine Interne 1982; 3(4): 367–372.
    1. Szodoray P, Hajas A, Toth L, et al. . The beneficial effect of plasmapheresis in mixed connective tissue disease with coexisting antiphospholipid syndrome. Lupus 2014; 23(10): 1079–1084.
    1. Van den Hoogen FH, Boerbooms AM, Van de Putte LB, et al. . Rebound of anti-topoisomerase I antibody titres after plasma exchange. Ann Rheum Dis 1993; 52(3): 246–247.
    1. Szúcs G, Szamosi S, Aleksza M, et al. . Plasmapheresis therapy in systemic sclerosis. Orv Hetil 2003; 144(45): 2213–2217.
    1. Farhey Y. Mixed connective tissue disease (MCTD): a coming of age. Curr Rheumatol Rev 2012; 8(1): 20–29.
    1. Cappelli S, Bellando Randone S, Martinović D, et al. . “To be or not to be,” ten years after: evidence for mixed connective tissue disease as a distinct entity. Semin Arthritis Rheum 2012; 41(4): 589–598.
    1. McLeod BC. Therapeutic apheresis: history, clinical application, and lingering uncertainties. Transfusion 2009; 50(7): 1413–1426.
    1. Harris AD, McGregor JC, Perencevich EN, et al. . The use and interpretation of quasi-experimental studies in medical informatics. J Am Med Inform Assoc 2006; 13(1): 16–23.
    1. Steen VD, Medsger TA. Improvement in skin thickening in systemic sclerosis associated with improved survival. Arthritis Rheum 2001; 44(12): 2828–2835.
    1. Wei N, Klippel JH, Huston DP, et al. . Randomised trial of plasma exchange in mild systemic lupus erythematosus. Lancet 1983; 1(8314–8315): 17–22.
    1. Raimann JG. Handbook of dialysis fifth edition by John T. Daugirdas, Peter G. Blake and Todd S. Ing. Philadelphia, PA: Lippincott Williams & Wilkins, 2014, 900 pp. (ISBN-13: 978-1451144291). Hemodial Int 2015; 19: 609–610.
    1. Derksen RH, Schuurman HJ, Meyling FH, et al. . The efficacy of plasma exchange in the removal of plasma components. J Lab Clin Med 1984; 104(3): 346–354.
    1. Brecher ME. Plasma exchange: why we do what we do. J Clin Apher 2002; 17(4): 207–211.
    1. Blunt RJ, George AJ, Hurlow RA, et al. . Hyperviscosity and thrombotic changes in idiopathic and secondary Raynaud’s syndrome. Br J Haematol 1980; 45(4): 651–658.
    1. Dintenfass L. Hemorheological factors in Raynaud’s phenomenon. Angiology 1977; 28(7): 472–481.
    1. Ernst E, Lohmaier EF, Meurer M, et al. . Decreased blood fluidity in progressive systemic scleroderma. Z Rheumatol 1990; 49(3): 155–159.
    1. Jacobs MJ, Breslau PJ, Slaaf DW, et al. . Nomenclature of Raynaud’s phenomenon: a capillary microscopic and hemorheologic study. Surgery 1987; 101(2): 136–145.
    1. Lacombe C, Mouthon JM, Bucherer C, et al. . Raynaud’s phenomenon and blood viscosity. J Mal Vasc 1992; 17(Suppl. B): 132–135.
    1. Larcan A, Schmidt C, Stoltz JF, et al. . Blood rheology in Raynaud’s disease. J Mal Vasc 1984; 9(1): 1–6.
    1. McGrath MA, Peek R, Penny R. Blood hyperviscosity with reduced skin blood flow in scleroderma. Ann Rheum Dis 1977; 36(6): 569–574.
    1. Picart C, Carpentier PH, Brasseur S, et al. . Systemic sclerosis: blood rheometry and laser Doppler imaging of digital cutaneous microcirculation during local cold exposure. Clin Hemorheol Microcirc 1998; 18(1): 47–58.
    1. Rustin MH, Kovacs IB, Sowemimo-Coker SO, et al. . Differences in red cell behaviour between patients with Raynaud’s phenomenon and systemic sclerosis and patients with Raynaud’s disease. Br J Dermatol 1985; 113(3): 265–272.
    1. Tietjen GW, Chien S, Leroy EC, et al. . Blood viscosity, plasma proteins, and Raynaud syndrome. Arch Surg 1975; 110(11): 1343–1346.
    1. Vayá A, Todolí J, Calvo J, et al. . Haemorheological profile in patients with systemic sclerosis. Clin Hemorheol Microcirc 2008; 40(3): 243–248.
    1. Korsten P, Niewold TB, Zeisberg M, et al. . Increased Whole Blood Viscosity Is Associated with the Presence of Digital Ulcers in Systemic Sclerosis: Results from a Cross-Sectional Pilot Study. Autoimmune Dis 2017; 2017: 1–5. doi:10.1155/2017/3529214
    1. Gudmundsson M, Bjelle A. Viscosity of plasma and blood in rheumatoid arthritis. Br J Rheumatol 1993; 32(9): 774–779.
    1. Rosenson RS, Shott S, Katz R. Elevated blood viscosity in systemic lupus erythematosus. Semin Arthritis Rheum 2001; 31(1): 52–57.
    1. Dwosh IL, Giles AR, Ford PM, et al. . Plasmapheresis therapy in rheumatoid arthritis. N Engl J Med 1983; 308(19): 1124–1129.
    1. Kahaleh MB, Sherer GK, LeRoy EC. Endothelial injury in scleroderma. J Exp Med 1979; 149(6): 1326–1335.
    1. Matucci-Cerinic M, Kahaleh B, Wigley FM. Review: evidence that systemic sclerosis is a vascular disease. Arthritis Rheum 2013; 65(8): 1953–1962.
    1. Kahaleh B. Vascular disease in scleroderma: mechanisms of vascular injury. Rheum Dis Clin North Am 2008; 34(1): 57–71.
    1. Kill A, Riemekasten G. Functional autoantibodies in systemic sclerosis pathogenesis. Curr Rheumatol Rep 2015; 17(5): 34.
    1. Cid J, Carbassé G, Andreu B, et al. . Efficacy and safety of plasma exchange: ann 11-year single-center experience of 2730 procedures in 317 patients. Transfus Apher Sci 2014; 51(2): 209–214.
    1. Mokrzycki MH, Balogun RA. Therapeutic apheresis: a review of complications and recommendations for prevention and management. J Clin Apher 2011; 26(5): 243–248.
    1. Khatri B, Kramer J. Vascular access for therapeutic plasma exchange. Muscle Nerve 2013; 48(4): 624.
    1. Costantino TG, Parikh AK, Satz WA, et al. . Ultrasonography-guided peripheral intravenous access versus traditional approaches in patients with difficult intravenous access. Ann Emerg Med 2005; 46(5): 456–461.
    1. Winters JL, Brown D, Hazard E, et al. . Cost-minimization analysis of the direct costs of TPE and IVIg in the treatment of Guillain-Barré syndrome. BMC Health Serv Res 2011; 11: 101.
    1. Howe A, Eyck L, Ten Dufour R, et al. . Treatment patterns and annual drug costs of biologic therapies across indications from the Humana commercial database. J Manag Care Spec Pharm 2014; 20(12): 1236–1244.
    1. Cantarini L, Rigante D, Vitale A, et al. . Intravenous immunoglobulins (IVIG) in systemic sclerosis: a challenging yet promising future. Immunol Res 2015; 61(3): 326–337.
    1. Poelman CL, Hummers LK, Wigley FM, et al. . Intravenous immunoglobulin may be an effective therapy for refractory, active diffuse cutaneous systemic sclerosis. J Rheumatol 2015; 42(2): 236–242.

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren